SCHEMBL4549116

SCHEMBL4549116

CCC(C)c1cc(C)cc(C(C)C)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
GABRA1 P14867 7/20 0.47
GABRB1 P18505 6/20 0.47
GABRB2 P47870 4/20 0.47
GSR P00390 1/20 0.44
TSHR P16473 2/20 0.44
RORC P51449 1/20 0.41
LMNA P02545 2/20 0.40
SLC6A2 P23975 2/20 0.40
HTR2B P41595 2/20 0.40
GABRA5 P31644 2/20 0.40
GABRA3 P34903 2/20 0.40
GABRA2 P47869 2/20 0.40
GABRA4 P48169 2/20 0.40
GABRA6 Q16445 2/20 0.40
FAAH O00519 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943323 0.94 TSHR (0.48) CA1CA2GABRA1GABRB1GABRB2
SCHEMBL14557201 0.88 TSHR (0.44) CA1CA2GABRA1GABRB1GABRB2
SCHEMBL13779538 0.86 CA1 (0.71) CA1CA2GABRA1GABRB1GABRB2
SCHEMBL544651 0.85 CA1 (0.67) CA1CA2GABRA1GABRB1GABRB2
SCHEMBL13640212 0.85 CA1 (0.47) CA1CA2GABRA1GABRB1GABRB2
SCHEMBL8760785 0.84 TSHR (0.44) CA1CA2TSHRRORCLMNA
SCHEMBL13640210 0.84 CA1 (0.50) CA1CA2GABRA1GABRB1GABRB2
SCHEMBL13636976 0.81 TSHR (0.41) GABRA1GABRB2TSHRRORCHPGD
SCHEMBL10893299 0.81 CA1 (0.47) CA1CA2GABRA1GABRB1GABRB2
SCHEMBL13447394 0.81 CA1 (0.47) CA1CA2GABRA1GABRB1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130217783-A1 Therapeutic Compounds SIGNATURE THERAPEUTICS, INC. (US) 2013-08-22 US disclosed
US-8350097-B2 Therapeutic compounds SIGNATURE THERAPEUTICS, INC. (US) 2013-01-08 US disclosed
US-20120196939-A1 Therapeutic Compounds SOWOOD HEALTHCARE LLC 2012-08-02 US disclosed
US-8173849-B2 Therapeutic compounds SIGNATURE THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
US-20100249246-A1 Therapeutic Compounds PHARMACOFORE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217783-A1 Therapeutic Compounds OPRM1, OGFR, UGT1A1 CA1 140/4885CA2 350/4885GABRA1 202/4885
US-20100249246-A1 Therapeutic Compounds OPRM1, OGFR, UGT1A1 CA1 140/4885CA2 350/4885GABRA1 202/4885
US-20120196939-A1 Therapeutic Compounds OPRM1, OPRD1, SCN1B CA1 476/4885CA2 752/4885GABRA1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.